MS402 disrupts the function of proteins that recognize and bind specific epigenetic marks, affecting the interpretation of epigenetic signals. It targets BRD2-BD1, BRD2-BD2, BRD3-BD1, BRD3-BD2, BRD4-BD1, and BRD4-BD2.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.